A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Metastatic Renal Cell Cancer Clinical Trial

Official title:

A Multicentre, Open Label, Early Stopping Design, Proof Of Concept Study With Tasquinimod In Treating Patients With Advanced Or Metastatic Hepatocellular, Ovarian, Renal Cell And Gastric Carcinomas

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01743469
• Other study ID #: 8-55-58102-004
• Secondary ID: 2012-002326-75
• Status: Completed
• Phase: Phase 2
• Start date: December 2012
• Est. completion date: April 2016

Study information

• Verified date: January 2019
• Source: Ipsen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This was an exploratory proof of concept study to determine the clinical activity of tasquinimod in patients with advanced or metastatic hepatocellular carcinoma, ovarian carcinoma, renal cell carcinoma and gastric carcinoma who had progressed after standard therapies.

Description:

This was an early stopping design, Phase II, open label, exploratory proof of concept study to evaluate the activity of tasquinimod in four independent cohorts of patients with different tumour types (patients with hepatocellular, ovarian, renal cell or gastric carcinoma, each with progressive disease after standard therapies). Patients initially received 0.5 mg/day tasquinimod dose, increasing to 1 mg/day after at least 2 weeks, unless there were any individual patient safety and tolerability concerns. The treatment period continued until patient disease progression, lost to follow-up, withdrawal or death. During the treatment period, initial study visits were at Week 2, 4 and 8 (± 2 days) for the hepatocellular carcinoma, the ovarian carcinoma and the renal cell carcinoma cohorts and at Week 2, 4 and 6 (± 2 days) for the gastric carcinoma cohort, to allow careful safety monitoring and to facilitate the identification of the individually tolerated dose. After Week 8, when most patients should have reached their tolerable dose, visit frequency was decreased as follows: at Week 16 and 24 (± 2 days) for the hepatocellular carcinoma, the ovarian carcinoma and the renal cell carcinoma cohorts; and at Week 12, 18 and 24 (± 2 days) for the gastric carcinoma cohort. Thereafter visits were once every 8 weeks (± 2 days) for all cohorts. An end of study treatment/withdrawal (EoST/WD) Visit was to be performed at least 14 days after the last dose of study treatment, and/or before treatment with any alternative antitumour therapy was started. Patients who stopped study treatment before disease progression were to be followed up with tumour imaging every 8 weeks until disease progression. Each patient was subsequently followed up for survival (by visit or telephone call) every 3 months after the EoST/WD Visit until death, lost to follow-up, or withdrawal of consent, or until all surviving patients had been followed-up for at least 9 months after their last administration of study treatment.

The clinical activity of tasquinimod was evaluated independently in each cohort of patients of the four different tumour types. Data were presented as of the following study cut-off dates:

• Hepatocellular carcinoma cohort: 03 December 2014 (efficacy data); 11 April 2016 (safety data).

• Ovarian carcinoma cohort: 27 November 2013 (efficacy data); 05 October 2015 (safety data).

• Renal cell carcinoma cohort: 04 December 2013.

• Gastric carcinoma cohort: 27 September 2013.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 201
• Est. completion date: April 2016
• Est. primary completion date: December 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria - All Patients:

1. Able and willing to provide written informed consent and to comply with the study protocol and procedures.

2. Age =18 years.

3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

4. Life expectancy greater than 3 months in the Investigator's opinion.

5. Disease progression during or after previous cancer treatment.

6. Measurable disease as per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria (v1.1).

7. The following time must have elapsed between previous therapy for cancer and first administration of tasquinimod:

• At least 2 weeks since previous systemic targeted therapy with small molecule inhibitors, which included any tyrosine-kinase inhibitor.

• At least 4 weeks since the last dose of systemic anti-cancer therapy other than targeted therapy, which included cytotoxic agents, monoclonal antibody therapy, immunotherapy and prior radiotherapy.

• At least 1 week since prior hormonal therapy.

• At least 3 months since prior interferon therapy.

8. Recovery to Grade 1 from the effects (excluding alopecia) of any prior therapy for their malignancies.

9. At least 4 weeks since any major surgery or open biopsy and 7 days since a core biopsy before first study treatment.

10. Adequate renal function:

• Creatinine =1.5 times upper limit of normal (ULN) or calculated creatinine clearance (CrCl) using the Cockcroft Gault formula =60 mL/min, or CrCl =60 mL/min.

11. Adequate hepatic function:

• Serum bilirubin =1.5 mg/dL (=25 µmol/L) for ovarian carcinoma, renal cell carcinoma and gastric carcinoma, serum bilirubin =3 mg/dL (=50 µmol/L) for hepatocellular carcinoma cohorts.

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5 x ULN (=5 x ULN if liver lesions were present i.e. liver metastasis or primary tumour of the liver for hepatocellular carcinoma cohort).

12. Adequate bone marrow function:

• Absolute neutrophil count (ANC) =1.5 x 10^9/L.

• Platelets =50 x 10^9/L.

• Haemoglobin =90 g/L.

13. Adequate coagulation tests: international normalised ratio (INR) =1.5 x ULN.

14. Able to swallow capsules.

15. For women of childbearing potential, a negative pregnancy test must have been documented prior to first administration of study treatment.

16. For women who were not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use adequate methods of contraception (e.g. hormonal implants, combined oral contraceptives, vasectomised partner), during the treatment period and for at least 3 months after the last dose of study treatment.

17. For men: agreement to use a barrier method of contraception during the treatment period and for at least 3 months after the last dose of study treatment.

Inclusion Criteria - Hepatocellular Carcinoma Cohort:

18. Histologically confirmed and documented hepatocellular carcinoma (excluding fibrolamellar carcinoma).

19. Barcelona Clinic Liver Cancer (BCLC) stage C or BCLC stage B not amenable to locoregional therapy or refractory to locoregional therapy.

20. Liver mass measuring at least 2 cm with characteristic vascularisation seen on either triphasic computed tomography (CT) scan or Magnetic Resonance Imaging (MRI) with gadolinium.

21. At least one measurable or evaluable lesion that was viable (i.e. vascularised), and had not been previously treated with locoregional therapy. A lesion that had been previously treated qualified as a measurable or evaluable lesion if there was demonstrable progression following locoregional therapy.

22. Child-Pugh A Class only.

23. Previously treated with sorafenib. Patients may have experienced radiographically documented disease progression during sorafenib therapy or after discontinuation of sorafenib therapy.

24. The patient had received sorafenib as the most recent systemic therapeutic intervention (any hepatic locoregional therapy that had been administered prior to sorafenib was allowed, but not following sorafenib; radiation to metastatic sites [e.g. bone] following sorafenib therapy was permitted).

Inclusion Criteria - Ovarian Carcinoma Cohort:

18. Histologically confirmed and documented ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer.

19. Progression within 6 months of a platinum containing chemotherapy regimen (i.e. platinum resistant).

20. Progression after up to three lines of chemotherapy.

21. Maximum one line treatment with antiangiogenic therapy.

Inclusion Criteria - Renal Cell Carcinoma Cohort:

18. Metastatic renal cell carcinoma.

19. Histologically or cytologically confirmed and documented renal cell carcinoma with a clear cell component.

20. Previous treatment with at least one vascular endothelial growth factor inhibitor.

21. Disease progression within 6 months prior to first study treatment.

22. Patient had at most two prior targeted therapies for unresectable advanced or metastatic disease.

Inclusion Criteria - Gastric Carcinoma Cohort:

18. Histologically or cytologically confirmed and documented adenocarcinoma of the stomach or gastroesophageal junction.

19. Unresectable advanced or initially metastatic or recurrent after curative resection.

20. Progression after one prior regimen of chemotherapy including fluoropyrimidine and platinum (with or without trastuzumab, if human epidermal growth factor receptor 2 positive [HER2+]).

21. Maximum one line treatment with antiangiogenic therapy.

Exclusion Criteria - All Patients:

1. Other primary malignancy within the past 3 years (except for fully-resected non-melanoma skin cancer, localised prostate cancer with normal prostate specific antigen level, or cervical cancer in situ).

2. Known central nervous system metastasis that was symptomatic and/or required treatment.

3. Malabsorption (other than in patients with gastric carcinoma and partial or complete gastrectomy) or intestinal obstruction.

4. History of pancreatitis.

5. Essential medications that are known potent inhibitors or inducers of CYP3A4.

6. Ongoing treatment with CYP1A2 (including warfarin) or CYP3A4 metabolised drug substance with narrow therapeutic range at the start of study. Treatment with low molecular weight heparin (LMWH) was permitted.

7. History of myocardial infarction, unstable angina, congestive heart failure New York Heart Association class III/IV, cerebrovascular accident, transient ischaemic attack, limb claudication at rest in the previous 6 months, or ongoing symptomatic dysrhythmias, or uncontrolled atrial, or ventricular arrhythmias, or uncontrolled hypertension defined as systolic blood pressure =150 mmHg or diastolic blood pressure =90 mmHg.

8. Evidence of bleeding diathesis or known coagulopathy.

9. History of venous thromboembolic disease within 3 months prior to first administration of study treatment.

10. The patient had current, severe and uncontrolled medical condition such as infection, diabetes mellitus or other systemic disease.

11. Any condition or illness that, in the opinion of the Investigator or the medical monitor, would have compromised patient safety or interfered with the evaluation of the safety of the drug.

12. Had known positive serology for human immunodeficiency virus.

13. Investigational drug within 28 days or within five times the elimination half-life (whichever was longest) prior to first dose of study treatment.

14. Known allergy to treatment medication or its excipients.

15. Breastfeeding.

Exclusion Criteria - Hepatocellular Carcinoma Cohort:

16. Fibrolamellar carcinoma.

Exclusion Criteria - Ovarian Carcinoma Cohort:

16. Non-epithelial cancer and borderline tumours (e.g. tumours of low malignant potential).

Exclusion Criteria - Gastric Carcinoma Cohort:

16. Other histologic type than adenocarcinoma.

Related Conditions & MeSH terms

• Advanced or Metastatic Gastric Carcinoma
• Advanced or Metastatic Hepatocellular Cancer
• Advanced or Metastatic Ovarian Cancer
• Carcinoma
• Carcinoma, Hepatocellular
• Carcinoma, Renal Cell
• Liver Neoplasms
• Metastatic Renal Cell Cancer
• Ovarian Neoplasms
• Stomach Neoplasms

Intervention

Drug:
• Tasquinimod
1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
• Tasquinimod
1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
• Tasquinimod
1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
• Tasquinimod
1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.

Locations

Country	Name	City	State
Belgium	Antwerp University Hospital, Wilrijkstraat 10	Edegem
Belgium	Ghent University Hospital, 1K12 IE, De Pintelaan 185	Gent
Belgium	Leuven cancer institute (LKI), Herestraat	Leuven
Canada	Juravinski Cancer Centre, 699 Concession St	Hamilton	Ontario
Canada	London Health Sciences Center, 790 Commissoners Road East	London	Ontario
Canada	Princess Margaret, 610 University Avenue	Toronto	Ontario
Canada	Sunnybrook, 2075 Bayview Avenue, Suite T2049	Toronto	Ontario
France	Hospital Beaujon, 100 Blvd du Général Leclerc	Clichy
France	Centre Oscar Lambret, 3 rue Frédéric Combemale	Lille cedex
France	Bureau d'Etudes Cliniques du Centre Léon Bérard, 28, rue Laennec	Lyon
France	Hopital Europeen Georges-Pompidou, AP-HP, 20 Rue Leblanc	Paris
France	Hospital Saint-Antoine, 184 rue du Faubourg St Antoine	Paris
France	Centre Eugene Marquis, Avenue bataille Flandres Dunkerque	Rennes cedex
France	Centre René Gauducheau, Boulevard Jacques Monod	Saint Herblain
France	Institute Gustave-Roussy, 114 rue Edouard Vaillant	Villejuif
Spain	Hospital del mar, Paseo Maritimo 25-29	Barcelona
Spain	Hospital Gregorio Marañon, Dr. Esquerdo, 44-46	Madrid
Spain	MD Anderson Cancer Centre, Ctra. Colmenar Viejo Km. 9 100,	Madrid
United Kingdom	Beatson West of Scotland Cancer Centre, 1053 Great Western Road	Glasgow
United Kingdom	Leicester General Hospital, Gwndolen Road	Leicester
United Kingdom	The Royal Marsden Hospital, Downs Rd, Sutton	London
United Kingdom	The Christie Hospital, Wilmslow Road, Withington	Manchester
United Kingdom	Freeman Hospital, Freeman Road, High Heaton	Newcastle-upon-Tyne
United Kingdom	Southampton General Hospital, Tremona Road, Shirley	Southampton

Sponsors (1)

Lead Sponsor	Collaborator
Ipsen

Countries where clinical trial is conducted

Belgium,  Canada,  France,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All Cohorts).	Progression (prog.) defined by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as a 20% increase in sum of longest diameter of target lesions,or a measurable increase in a nontarget lesion,or appearance of new lesions.; 'Progressed or Died' when time between start of study drug &first date of the following events was = to analysis timepoint +3 days:1) Disease prog. according to central review using RECIST v1.1:date of disease prog. or if missing,first exam date of the visit showing a disease prog.2) Death due to any cause.; 'Neither progressed, nor died' if central assessment by RECIST v1.1 confirmed no disease prog. was observed at the considered timepoint,i.e. time between start of study medication &last examination/visit date of complete response (CR),partial response (PR) or stable disease (SD) = analysis timepoint 7days.In other cases, such as patient withdrawal due to AEs without tumor assessment proving prog.,the patient was considered as 'not assessable'.	Week 12 (Gastric Carcinoma Cohort); Week 16 (Hepatocellular and Renal Cell Carcinoma Cohorts); Week 24 (Ovarian Carcinoma Cohort).
Secondary	PFS Rate Measured by Choi Criteria (Hepatocellular Carcinoma Cohort).	PFS rate was defined as the percentage of patients who had neither progressed nor died. Tumour progression was assessed centrally using the Choi criteria.; Response was measured using the following criteria: CR: Disappearance of all lesions, no new lesions; PR: A decrease in size =10% or a decrease in tumour attenuation (Hounsfield unit [HU]) =15% on CT, no new lesions, no obvious progression of non-measurable disease; SD: Does not meet criteria for CR, PR, or progressive disease (PD), no symptomatic deterioration attributed to tumour progression; PD: An increase in tumour size =10% and does not meet criteria of PR by tumour attenuation on CT, new lesions.	Week 16.
Secondary	Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed).	Best overall response was derived as the best overall response documented before the prespecified timepoint (gastric carcinoma cohort: 12 weeks; Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.	Every 6 weeks until Week 24, thereafter, every 8 weeks until disease progression, up to 36 months (gastric carcinoma cohort); every 8 weeks until disease progression, up to 36 months (all other cohorts).
Secondary	Best Overall Response and Response Rate Based on Choi Criteria (Hepatocellular Carcinoma Cohort).	Per Choi Criteria for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=10% decrease in the sum of the longest diameter of target lesions; Progression, as a 10% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.	Every 8 weeks until disease progression, up to 36 months.
Secondary	Clinical Benefit (All Cohorts).	Clinical benefit was defined as CR, PR or SD lasting at least 12 weeks using centrally or locally assessed RECIST v1.1.	Every 6 weeks until Week 24, thereafter, every 8 weeks until disease progression, up to 36 months (gastric carcinoma cohort); every 8 weeks until disease progression, up to 36 months (all other cohorts).
Secondary	PFS From First Study Treatment to Progression or Death Due to Any Cause Based on Choi Criteria (Hepatocellular Carcinoma Cohort).	PFS defined as the time from first study treatment to the first occurrence of a disease progression according to centrally assessed Choi criteria (i.e. increase in tumor size =10%) or death due to any cause before initiation of new systemic treatment.	Every 8 weeks until disease progression, up to 36 months.
Secondary	PFS From First Study Treatment to Progression or Death Due to Any Cause Based on RECIST v1.1 Criteria (All Cohorts).	PFS defined as the time from first study treatment to the first occurrence of a disease progression according to centrally and locally assessed RECIST v1.1 (i.e. increase in tumor size =20%) or death due to any cause before initiation of new systemic treatment.	Every 6 weeks until Week 24, thereafter, every 8 weeks until disease progression, up to 36 months (gastric carcinoma cohort); every 8 weeks until disease progression, up to 36 months (all other cohorts).
Secondary	Time to Progression (TTP) by Choi Criteria (Hepatocellular Carcinoma Cohort).	TTP defined as the time from first study treatment to the first occurrence of disease progression defined according to centrally assessed Choi criteria (i.e. increase in tumor size =10%) or death due to disease progression before initiation of a new systemic treatment.	Every 8 weeks until disease progression, up to 36 months.
Secondary	TTP by RECIST v1.1 (All Cohorts).	TTP was defined as the time from first study treatment to the first occurrence of disease progression defined according to centrally and locally assessed RECIST v1.1 criteria (i.e. increase in tumor size =20%) or death due to disease progression before initiation of a new systemic treatment.	Every 6 weeks until Week 24, thereafter, every 8 weeks until disease progression, up to 36 months (gastric carcinoma cohort); every 8 weeks until disease progression, up to 36 months (all other cohorts).
Secondary	Overall Survival (OS), Defined as the Time From First Study Treatment to Death Due to Any Cause (All Cohorts).	OS is the time (in weeks) from the first study medication date to death due to any cause. Patients were censored at the date of last contact (the latest between the time of EoST/WD assessment and follow-up visits).; OS was estimated using Kaplan-Meier analysis.	Time from first study treatment to death, up to 36 months.
Secondary	Further Cancer-related Treatment During Follow-up Period (All Cohorts).	Further systemic treatment was coded using World Health Organization (WHO) Drug Dictionary (versions: June 2014 for the hepatocellular carcinoma cohort and June 2013 for the ovarian, renal cell and gastric carcinoma cohorts).; A frequency table of the number and percentage of patients was provided by Anatomical Therapeutic Chemical (ATC) decode and preferred name.	16 weeks, Last Patient First Treatment + 16 weeks.